About Us
Kalohexis is a clinical-stage biotechnology company focused on developing innovative treatments for obesity and metabolic diseases. The company uses the body's natural melanocortin (MC) system, which helps regulate metabolism, to develop targeted peptide therapies.
Its leading drug candidates include 710GO, an oral treatment designed to support more sustainable weight loss, and mifomelatide, a therapy being developed to prevent and treat cachexia (severe weight and muscle loss) in patients with advanced cancer.
Kalohexis is also exploring treatments for other conditions, including type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), opioid use disorder, sarcopenia, polycystic ovary syndrome (PCOS), muscle preservation, and menopausal weight management.
Through research and innovation, Kalohexis aims to improve metabolic health and develop new treatment options for patients with unmet medical needs.
Website: https://www.kalohexis.com
